GI
BLRX

Gradient Investments’s BioLineRX BLRX Stock Holding History

Gradient Investments’s Portfolio BLRX Stock Details BLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,035
Closed -$8.86K – 321
2024
Q4 		$8.86K Buy
1,035
+285
+38% +$4.2K ﹤0.01% 297
2024
Q3 		$16.1K Hold
750
– – ﹤0.01% 298
2024
Q2 		$17.1K Buy
750
+525
+233% +$14.1K ﹤0.01% 664
2024
Q1 		$10.1K Buy
225
+177
+369% +$8.88K ﹤0.01% 639
2023
Q4 		$2.98K Hold
48
– – ﹤0.01% 1121
2023
Q3 		$3.46K Buy
+48
New +$3.23K ﹤0.01% 1042

Other funds holding BLRX

Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
NRG
Nemes Rush Group Novi, Michigan $1.05B AUM 30.08% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Gradient Investments's BLRX Position: Q1 2025 in Review

Gradient Investments sold out of BioLineRX (BLRX) in Q1 2025, closing a stake of 1,035 shares — an estimated $8.86K sold.

Gradient Investments first reported a position in BLRX in Q3 2023 and held it in 6 quarters. The position peaked at $17.1K in Q2 2024. 12 funds tracked by Wall St. Rank hold BLRX as of Q1 2025.

  • Gradient Investments reported no remaining BioLineRX position as of Q1 2025 after selling out during the quarter.
  • Gradient Investments sold 1,035 BioLineRX shares in Q1 2025, an estimated $8.86K.
  • Gradient Investments first reported a position in BioLineRX in Q3 2023 and held it in 6 quarters.
  • Gradient Investments's BioLineRX position peaked at $17.1K in Q2 2024.
  • 12 funds tracked by Wall St. Rank held BioLineRX as of Q1 2025.

Based on Gradient Investments's 13F filing for Q1 2025, filed 9 Apr 2025.